Browsing Tag
VYVGART
3 posts
Could FcRn blockers become the next biologics blockbuster class after interleukin inhibitors and JAKs?
A new frontier is emerging in the world of biologic therapies. After years of dominance by interleukin inhibitors…
How does nipocalimab compare to efgartigimod and rozanolixizumab? FcRn class battlelines in gMG and beyond
Compare nipocalimab, efgartigimod, and rozanolixizumab on efficacy, safety, dosing, pricing, and market strategy in generalized myasthenia gravis treatment.
argenx wins EU approval for subcutaneous VYVGART in CIDP, ending 30-year innovation drought in treatment
argenx gains EU approval for subcutaneous VYVGART in CIDP, reshaping autoimmune neurology care with a novel self-injection biologic.